Thermo Fisher’s Stock Slumps 0.88% on 95th-Ranked $1.01B Volume Amid Sector Turmoil

On October 7, 2025, Thermo Fisher Scientific (TMO) closed at a 0.88% decline with a trading volume of $1.01 billion, marking a 27.15% drop from the previous day’s volume. The stock ranked 95th in trading activity among U.S. equities, reflecting mixed investor sentiment amid sector-specific dynamics.

Analysts noted that recent regulatory scrutiny and supply chain adjustments within the life sciences sector may have contributed to the stock’s volatility. While no direct earnings or partnership announcements were reported, industry observers highlighted broader market concerns over capital expenditure cycles in biotechnology research, a core segment for Thermo’s revenue streams. The decline aligns with a broader trend of reduced liquidity in large-cap healthcare names, though sector peers exhibited varied performance patterns.

To run this back-test robustly I need to pin down a few details: 1. Universe • Should the selection pool be “all U.S. common stocks” (NYSE + NASDAQ + AMEX), or a narrower list such as the current S&P 1500 constituents? 2. Trade-time convention • Enter at today’s close and exit at tomorrow’s close (close-to-close)? • Or enter at tomorrow’s open and exit at tomorrow’s close (close-to-open)? 3. Price data vendor / adjustment • Is it acceptable to use split- and dividend-adjusted prices? 4. Transaction costs • Assume zero commissions/slippage, or apply an estimate? 5. Weighting • Equal-weight each of the 500 names, or weight by dollar volume / market-cap? 6. Benchmark (optional) • Compare versus SPY, equal-weighted universe, or no benchmark? Let me know your preferences and I’ll build the back-test.